Rapid decrease in titer and breadth of neutralizing anti-HCV antibodies in HIV/HCV-coinfected patients who achieved SVR

Lorena Vigón; Sonia Vázquez-Morón; Juan Berenguer; Juan González-García; Ma Ángeles Jiménez-Sousa; Jose Maria Guardiola Tey; Manuel Crespo Casal; Ignacio de los Santos Gil; Miguel Ángel Von Wichmann; Ana Carrero; María Belén Yélamos; Julián Gómez; Salvador Resino; Isidoro Martínez; P. Miralles; J.C. López; F. Parras; B. Padilla; T Aldámiz-Echevarría; F. Tejerina; Cristina Diez; L. Pérez-Latorre; Chiara Fanciulli; I. Gutiérrez; M. Ramírez; S. Carretero; J.M. Bellón; Javier Bermejo; V. Hontañón; Jose Arribas; M.L. Montes; I. Bernardino; J.F. Pascual; Francisco Zamora; J.M. Peña; F. Arnalich; M. Díaz; Pere Domingo; J. Sanz; M.J. Bustinduy; José Antonio Iribarren; F. Rodríguez-Arrondo; E.Van den Eynde; M. Pérez; E. Ribera; José Luis Casado; Fernando Dronda; A. Moreno; Mª Jesus Pérez Elías; M.A. Sanfrutos; S. Moreno; Carmen Quereda; A. Arranz; E. Casas; J.de Miguel; S. Schroeder; J. Vergas; M.J. Téllez; D. Vinuesa; L. Muñoz; José Hernández Quero; A. Ferrer; M.J. Galindo; L. Ortiz; E. Ortega; M. Montero; M. Blanes; S. Cuellar; José Lacruz; M. Salavert; J. López-Aldeguer; G. Pérez; G. Gaspar; M. Yllescas; P. Crespo; E. Aznar; H. Esteban

doi:10.1038/s41598-019-48592-5

Rapid decrease in titer and breadth of neutralizing anti-HCV antibodies in HIV/HCV-coinfected patients who achieved SVR

Lorena Vigón, Sonia Vázquez-Morón, Juan Berenguer, Juan González-García, Ma Ángeles Jiménez-Sousa, Jose Maria Guardiola Tey, Manuel Crespo Casal, Ignacio de los Santos Gil, Miguel Ángel Von Wichmann, Ana Carrero, María Belén Yélamos, Julián Gómez, Salvador Resino, Isidoro Martínez, P. Miralles, J.C. López, F. Parras, B. Padilla, T Aldámiz-Echevarría, F. TejerinaCristina Diez, L. Pérez-Latorre, Chiara Fanciulli, I. Gutiérrez, M. Ramírez, S. Carretero, J.M. Bellón, Javier Bermejo, V. Hontañón, Jose Arribas, M.L. Montes, I. Bernardino, J.F. Pascual, Francisco Zamora, J.M. Peña, F. Arnalich, M. Díaz, Pere Domingo, J. Sanz, M.J. Bustinduy, José Antonio Iribarren, F. Rodríguez-Arrondo, E.Van den Eynde, M. Pérez, E. Ribera, José Luis Casado, Fernando Dronda, A. Moreno, Mª Jesus Pérez Elías, M.A. Sanfrutos, S. Moreno, Carmen Quereda, A. Arranz, E. Casas, J.de Miguel, S. Schroeder, J. Vergas, M.J. Téllez, D. Vinuesa, L. Muñoz, José Hernández Quero, A. Ferrer, M.J. Galindo, L. Ortiz, E. Ortega, M. Montero, M. Blanes, S. Cuellar, José Lacruz, M. Salavert, J. López-Aldeguer, G. Pérez, G. Gaspar, M. Yllescas, P. Crespo, E. Aznar, H. Esteban

Departament de Medicina

Producció científica: Contribució a revista › Article › Recerca › Avaluat per experts

3 Cites (Scopus)

Resum

The main targets for neutralizing anti-hepatitis C virus (HCV) antibodies (HCV-nAbs) are the E1 and E2 envelope glycoproteins. We have studied the characteristics of HCV-nAbs through a retrospective study involving 29 HIV/HCV-coinfected patients who achieved sustained virological response (SVR) with peg-IFNα + ribavirin anti-HCV therapy. Plasma samples at baseline and week 24 after SVR were used to perform neutralization assays against five JFH1-based HCV recombinant viruses coding for E1 and E2 from genotypes 1a (H77), 1b (J4), 2a (JFH1), 3a (S52) and 4a (ED43). At baseline, the majority of plasma samples neutralized 1a, 1b, 2a, and 4a, but not 3a, genotypes. Twenty-four weeks following SVR, most neutralizing titers declined substantially. Furthermore, titers against 3a and 2a were not detected in many patients. Plasma samples with high HCV-nAb titers neutralized all genotypes, and the highest titers at the starting point correlated with the highest titers at week 24 after SVR. In conclusion, high titers of broad-spectrum HCV-nAbs were detected in HIV/HCV-coinfected individuals, however, those titers declined soon after SVR.

Idioma original	Anglès
Revista	Scientific reports
Volum	9
Número	1
DOIs	https://doi.org/10.1038/s41598-019-48592-5
Estat de la publicació	Publicada - 2019

SDG de les Nacions Unides

Aquest resultat contribueix als següents objectius de desenvolupament sostenible.

Accés al document

10.1038/s41598-019-48592-5

https://ddd.uab.cat/record/286570

Altres arxius i enllaços

https://www.scopus.com/pages/publications/85071102547

Com citar-ho

Vigón, L., Vázquez-Morón, S., Berenguer, J., González-García, J., Jiménez-Sousa, M. Á., Guardiola Tey, J. M., Crespo Casal, M., de los Santos Gil, I., Von Wichmann, M. Á., Carrero, A., Yélamos, M. B., Gómez, J., Resino, S., Martínez, I., Miralles, P., López, J. C., Parras, F., Padilla, B., Aldámiz-Echevarría, T., ... Esteban, H. (2019). Rapid decrease in titer and breadth of neutralizing anti-HCV antibodies in HIV/HCV-coinfected patients who achieved SVR. Scientific reports, 9(1). https://doi.org/10.1038/s41598-019-48592-5

@article{d2e46f180be34c29b07a2791238b0edc,

title = "Rapid decrease in titer and breadth of neutralizing anti-HCV antibodies in HIV/HCV-coinfected patients who achieved SVR",

abstract = "The main targets for neutralizing anti-hepatitis C virus (HCV) antibodies (HCV-nAbs) are the E1 and E2 envelope glycoproteins. We have studied the characteristics of HCV-nAbs through a retrospective study involving 29 HIV/HCV-coinfected patients who achieved sustained virological response (SVR) with peg-IFNα + ribavirin anti-HCV therapy. Plasma samples at baseline and week 24 after SVR were used to perform neutralization assays against five JFH1-based HCV recombinant viruses coding for E1 and E2 from genotypes 1a (H77), 1b (J4), 2a (JFH1), 3a (S52) and 4a (ED43). At baseline, the majority of plasma samples neutralized 1a, 1b, 2a, and 4a, but not 3a, genotypes. Twenty-four weeks following SVR, most neutralizing titers declined substantially. Furthermore, titers against 3a and 2a were not detected in many patients. Plasma samples with high HCV-nAb titers neutralized all genotypes, and the highest titers at the starting point correlated with the highest titers at week 24 after SVR. In conclusion, high titers of broad-spectrum HCV-nAbs were detected in HIV/HCV-coinfected individuals, however, those titers declined soon after SVR.",

keywords = "Antibodies, Hepatitis C, Hepatitis C virus",

author = "Lorena Vig{\'o}n and Sonia V{\'a}zquez-Mor{\'o}n and Juan Berenguer and Juan Gonz{\'a}lez-Garc{\'i}a and Jim{\'e}nez-Sousa, \{Ma {\'A}ngeles\} and \{Guardiola Tey\}, \{Jose Maria\} and \{Crespo Casal\}, Manuel and \{de los Santos Gil\}, Ignacio and \{Von Wichmann\}, \{Miguel {\'A}ngel\} and Ana Carrero and Y{\'e}lamos, \{Mar{\'i}a Bel{\'e}n\} and Juli{\'a}n G{\'o}mez and Salvador Resino and Isidoro Mart{\'i}nez and P. Miralles and J.C. L{\'o}pez and F. Parras and B. Padilla and T Ald{\'a}miz-Echevarr{\'i}a and F. Tejerina and Cristina Diez and L. P{\'e}rez-Latorre and Chiara Fanciulli and I. Guti{\'e}rrez and M. Ram{\'i}rez and S. Carretero and J.M. Bell{\'o}n and Javier Bermejo and V. Honta{\~n}{\'o}n and Jose Arribas and M.L. Montes and I. Bernardino and J.F. Pascual and Francisco Zamora and J.M. Pe{\~n}a and F. Arnalich and M. D{\'i}az and Pere Domingo and J. Sanz and M.J. Bustinduy and Iribarren, \{Jos{\'e} Antonio\} and F. Rodr{\'i}guez-Arrondo and Eynde, \{E.Van den\} and M. P{\'e}rez and E. Ribera and Casado, \{Jos{\'e} Luis\} and Fernando Dronda and A. Moreno and \{P{\'e}rez El{\'i}as\}, \{Mª Jesus\} and M.A. Sanfrutos and S. Moreno and Carmen Quereda and A. Arranz and E. Casas and J.de Miguel and S. Schroeder and J. Vergas and M.J. T{\'e}llez and D. Vinuesa and L. Mu{\~n}oz and \{Hern{\'a}ndez Quero\}, Jos{\'e} and A. Ferrer and M.J. Galindo and L. Ortiz and E. Ortega and M. Montero and M. Blanes and S. Cuellar and Jos{\'e} Lacruz and M. Salavert and J. L{\'o}pez-Aldeguer and G. P{\'e}rez and G. Gaspar and M. Yllescas and P. Crespo and E. Aznar and H. Esteban",

year = "2019",

doi = "10.1038/s41598-019-48592-5",

language = "English",

volume = "9",

number = "1",

}

Vigón, L, Vázquez-Morón, S, Berenguer, J, González-García, J, Jiménez-Sousa, MÁ, Guardiola Tey, JM, Crespo Casal, M, de los Santos Gil, I, Von Wichmann, MÁ, Carrero, A, Yélamos, MB, Gómez, J, Resino, S, Martínez, I, Miralles, P, López, JC, Parras, F, Padilla, B, Aldámiz-Echevarría, T, Tejerina, F, Diez, C, Pérez-Latorre, L, Fanciulli, C, Gutiérrez, I, Ramírez, M, Carretero, S, Bellón, JM, Bermejo, J, Hontañón, V, Arribas, J, Montes, ML, Bernardino, I, Pascual, JF, Zamora, F, Peña, JM, Arnalich, F, Díaz, M, Domingo, P, Sanz, J, Bustinduy, MJ, Iribarren, JA, Rodríguez-Arrondo, F, Eynde, EVD, Pérez, M, Ribera, E, Casado, JL, Dronda, F, Moreno, A, Pérez Elías, MJ, Sanfrutos, MA, Moreno, S, Quereda, C, Arranz, A, Casas, E, Miguel, JD, Schroeder, S, Vergas, J, Téllez, MJ, Vinuesa, D, Muñoz, L, Hernández Quero, J, Ferrer, A, Galindo, MJ, Ortiz, L, Ortega, E, Montero, M, Blanes, M, Cuellar, S, Lacruz, J, Salavert, M, López-Aldeguer, J, Pérez, G, Gaspar, G, Yllescas, M, Crespo, P, Aznar, E & Esteban, H 2019, 'Rapid decrease in titer and breadth of neutralizing anti-HCV antibodies in HIV/HCV-coinfected patients who achieved SVR', Scientific reports, vol. 9, núm. 1. https://doi.org/10.1038/s41598-019-48592-5

TY - JOUR

T1 - Rapid decrease in titer and breadth of neutralizing anti-HCV antibodies in HIV/HCV-coinfected patients who achieved SVR

AU - Vigón, Lorena

AU - Vázquez-Morón, Sonia

AU - Berenguer, Juan

AU - González-García, Juan

AU - Jiménez-Sousa, Ma Ángeles

AU - Guardiola Tey, Jose Maria

AU - Crespo Casal, Manuel

AU - de los Santos Gil, Ignacio

AU - Von Wichmann, Miguel Ángel

AU - Carrero, Ana

AU - Yélamos, María Belén

AU - Gómez, Julián

AU - Resino, Salvador

AU - Martínez, Isidoro

AU - Miralles, P.

AU - López, J.C.

AU - Parras, F.

AU - Padilla, B.

AU - Aldámiz-Echevarría, T

AU - Tejerina, F.

AU - Diez, Cristina

AU - Pérez-Latorre, L.

AU - Fanciulli, Chiara

AU - Gutiérrez, I.

AU - Ramírez, M.

AU - Carretero, S.

AU - Bellón, J.M.

AU - Bermejo, Javier

AU - Hontañón, V.

AU - Arribas, Jose

AU - Montes, M.L.

AU - Bernardino, I.

AU - Pascual, J.F.

AU - Zamora, Francisco

AU - Peña, J.M.

AU - Arnalich, F.

AU - Díaz, M.

AU - Domingo, Pere

AU - Sanz, J.

AU - Bustinduy, M.J.

AU - Iribarren, José Antonio

AU - Rodríguez-Arrondo, F.

AU - Eynde, E.Van den

AU - Pérez, M.

AU - Ribera, E.

AU - Casado, José Luis

AU - Dronda, Fernando

AU - Moreno, A.

AU - Pérez Elías, Mª Jesus

AU - Sanfrutos, M.A.

AU - Moreno, S.

AU - Quereda, Carmen

AU - Arranz, A.

AU - Casas, E.

AU - Miguel, J.de

AU - Schroeder, S.

AU - Vergas, J.

AU - Téllez, M.J.

AU - Vinuesa, D.

AU - Muñoz, L.

AU - Hernández Quero, José

AU - Ferrer, A.

AU - Galindo, M.J.

AU - Ortiz, L.

AU - Ortega, E.

AU - Montero, M.

AU - Blanes, M.

AU - Cuellar, S.

AU - Lacruz, José

AU - Salavert, M.

AU - López-Aldeguer, J.

AU - Pérez, G.

AU - Gaspar, G.

AU - Yllescas, M.

AU - Crespo, P.

AU - Aznar, E.

AU - Esteban, H.

PY - 2019

Y1 - 2019

N2 - The main targets for neutralizing anti-hepatitis C virus (HCV) antibodies (HCV-nAbs) are the E1 and E2 envelope glycoproteins. We have studied the characteristics of HCV-nAbs through a retrospective study involving 29 HIV/HCV-coinfected patients who achieved sustained virological response (SVR) with peg-IFNα + ribavirin anti-HCV therapy. Plasma samples at baseline and week 24 after SVR were used to perform neutralization assays against five JFH1-based HCV recombinant viruses coding for E1 and E2 from genotypes 1a (H77), 1b (J4), 2a (JFH1), 3a (S52) and 4a (ED43). At baseline, the majority of plasma samples neutralized 1a, 1b, 2a, and 4a, but not 3a, genotypes. Twenty-four weeks following SVR, most neutralizing titers declined substantially. Furthermore, titers against 3a and 2a were not detected in many patients. Plasma samples with high HCV-nAb titers neutralized all genotypes, and the highest titers at the starting point correlated with the highest titers at week 24 after SVR. In conclusion, high titers of broad-spectrum HCV-nAbs were detected in HIV/HCV-coinfected individuals, however, those titers declined soon after SVR.

AB - The main targets for neutralizing anti-hepatitis C virus (HCV) antibodies (HCV-nAbs) are the E1 and E2 envelope glycoproteins. We have studied the characteristics of HCV-nAbs through a retrospective study involving 29 HIV/HCV-coinfected patients who achieved sustained virological response (SVR) with peg-IFNα + ribavirin anti-HCV therapy. Plasma samples at baseline and week 24 after SVR were used to perform neutralization assays against five JFH1-based HCV recombinant viruses coding for E1 and E2 from genotypes 1a (H77), 1b (J4), 2a (JFH1), 3a (S52) and 4a (ED43). At baseline, the majority of plasma samples neutralized 1a, 1b, 2a, and 4a, but not 3a, genotypes. Twenty-four weeks following SVR, most neutralizing titers declined substantially. Furthermore, titers against 3a and 2a were not detected in many patients. Plasma samples with high HCV-nAb titers neutralized all genotypes, and the highest titers at the starting point correlated with the highest titers at week 24 after SVR. In conclusion, high titers of broad-spectrum HCV-nAbs were detected in HIV/HCV-coinfected individuals, however, those titers declined soon after SVR.

KW - Antibodies

KW - Hepatitis C

KW - Hepatitis C virus

UR - https://www.scopus.com/pages/publications/85071102547

U2 - 10.1038/s41598-019-48592-5

DO - 10.1038/s41598-019-48592-5

M3 - Article

C2 - 31434968

SN - 2045-2322

VL - 9

JO - Scientific reports

JF - Scientific reports

IS - 1

ER -

Rapid decrease in titer and breadth of neutralizing anti-HCV antibodies in HIV/HCV-coinfected patients who achieved SVR

Resum

SDG de les Nacions Unides

Accés al document

Altres arxius i enllaços

Fingerprint

Com citar-ho